Breaking News
July 17, 2018 - Can-Fite BioPharma receives Australian and Chinese patents for new drug to treat erectile dysfunction
July 17, 2018 - AAP: Lawnmowers Pose Serious Injury Risk to Children
July 17, 2018 - Fewer U.S. kids are getting cavities
July 17, 2018 - Differences in brain’s reward circuit may explain social deficits in autism
July 17, 2018 - YCC researchers suggest promising treatment for two rare inherited cancer syndromes
July 17, 2018 - FAU and partners receive NIH research grant to shed light on sleep loss and metabolic disorders
July 17, 2018 - Advanced MRI technique predicts risk of disease progression in MS
July 17, 2018 - Health Tip: Microwave Safely – Drugs.com MedNews
July 17, 2018 - New target for treating heart failure identified
July 17, 2018 - Biodesign fellows simplify heart rhythm monitoring
July 17, 2018 - Study reveals new risk genes for allergic rhinitis
July 17, 2018 - Community college education can increase physician diversity and access to primary care
July 17, 2018 - Inflection Biosciences’ dual mechanism inhibitor shows promise as treatment for CLL
July 17, 2018 - Researchers uncover how cells invite corrupted proteins inside
July 17, 2018 - Studies show HORIBA’s new hematology analyzer improves POCT and care of oncology patients
July 17, 2018 - New website aims to make yoga safer for everyone
July 17, 2018 - Long-term survival worse for black survivors of in-hospital cardiac arrest
July 17, 2018 - Stanford data analyst’s childhood inspires his research: A Q&A
July 17, 2018 - Preventability of hospital readmissions changes over time, study reveals
July 17, 2018 - Nursing notes can help predict if ICU patients will survive
July 17, 2018 - Okayama University research could improve prognosis of diabetic kidney disease
July 17, 2018 - Researchers develop machine learning method to predict unknown gene functions of microbes
July 17, 2018 - Homogenous BTK occupancy assay used in tirabrutinib clinical studies
July 17, 2018 - Study identifies new genes linked to heart function and development
July 17, 2018 - NeuroTrauma Sciences and Henry Ford join hands to advance exosome technology
July 17, 2018 - Improved methods to measure enterococci concentrations in recreational water
July 17, 2018 - White adolescent boys experiencing early puberty have high risk for substance use
July 17, 2018 - Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 17, 2018 - Roots of leukemia reveal possibility of predicting people at risk
July 17, 2018 - Summer med program embraces low-income students’ potential
July 17, 2018 - New research lays foundation to create standards for RNA sequencing
July 17, 2018 - CRISPR/Cas9 gene editing can cause greater genetic damage than previously thought
July 17, 2018 - Democrats rally against threats to the ACA to block Trump’s Supreme Court nominee
July 17, 2018 - Staggering prices slow insurers’ coverage of CAR-T cancer therapy
July 17, 2018 - How proteins involved in neurodegeneration enter cells
July 17, 2018 - New super-resolution ‘nanoscope’ provides insight into progression of Alzheimer’s disease
July 17, 2018 - FDA Advisory Committee Endorses the Effectiveness and Safety of Single-Dose Tafenoquine for the Radical Cure of P. vivax Malaria
July 17, 2018 - Uncovering the evolutionary history of IBD-associated colorectal cancer
July 17, 2018 - Is nutrition research dependable? Stanford’s John Ioannidis weighs in
July 17, 2018 - New machine learning framework predicts effects of genetic mutations in ‘dark matter’ regions
July 17, 2018 - Plant-based products fail to have positive impact on blood pressure during clinical studies
July 17, 2018 - Electronic system to speed up facial pain diagnosis may improve quality of life and save money
July 17, 2018 - Study delves into the role played by Protein Kinase C in synaptic plasticity
July 17, 2018 - Women Often Unaware of Their Hospital’s Religious Affiliation
July 17, 2018 - New AASM guideline recommends use of actigraphy for sleep disorders
July 17, 2018 - CRISPR editing reduces repetitive behavior in mice with a form of autism
July 17, 2018 - Scientists use magnets to detect cancer
July 17, 2018 - Microfluidic chip to detect sepsis proves successful in clinical study
July 17, 2018 - Research provides better understanding of mechanisms underlying memory storage
July 17, 2018 - A Multi-Modal Approach for the Early Detection of Breast Cancer
July 17, 2018 - Mailing colorectal cancer tests to patients increases screening rates, report researchers
July 17, 2018 - Scientists find possible sources of medicinal and antimicrobial drugs
July 17, 2018 - Molecules formed when the body metabolizes omega-3 fatty acids may inhibit cancer
July 17, 2018 - Efficient communication between hospitals improves patient safety and reduces mortality
July 17, 2018 - Study highlights potential of fetal gene therapy to prevent lethal neurodegenerative disease
July 17, 2018 - For Americans, in Science They Trust
July 17, 2018 - Combating HIV/AIDS | NIH MedlinePlus the Magazine
July 17, 2018 - Study shows minorities widely underrepresented in autism diagnoses
July 17, 2018 - Multigene testing replacing BRCA tests for breast cancer risk | News Center
July 17, 2018 - Pre-clinical pilot study shows promising results of ‘concussion pill’
July 17, 2018 - Researchers reduce size of tumors in mice by artificially activating the brain’s reward system
July 17, 2018 - New study documents symptoms of people before they acquire multiple sclerosis
July 17, 2018 - Researchers discover why CRISPR gene editing sometimes fails
July 17, 2018 - New finding may hold key to better understand the complexities of neurological disorders
July 17, 2018 - The Current issue of “The view from here” is concerned with Novel Targets.
July 17, 2018 - Fighting the Flu with a Universal Vaccine
July 17, 2018 - Key social reward circuit in the brain impaired in kids with autism | News Center
July 17, 2018 - Insight into causes, types and treatment of aphasia
July 16, 2018 - Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery
July 16, 2018 - NSAIDs shown to have causal role in cardiovascular risk of patients with osteoarthritis
July 16, 2018 - PET scan tracer predicts success of cancer ‘vaccine’ | News Center
July 16, 2018 - Parents struggle with what to do when their child has headache, shows study
July 16, 2018 - Outrageous or overblown? HHS announces another round of ACA navigator funding cuts
July 16, 2018 - Weight loss surgery may impact individual’s risk of developing cancer, shows study
July 16, 2018 - Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
July 16, 2018 - Restoring epigenetic balance reinstates memory in flies with Alzheimer’s disease symptoms
July 16, 2018 - Magnetized wire could be used to detect cancer in people | News Center
July 16, 2018 - Non-surgical management found to be feasible option for penetrating kidney trauma
July 16, 2018 - California clinic screens asylum seekers for honesty
July 16, 2018 - FDA Approves Xtandi (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Financial savings lower than anticipated for generic oral chemotherapy

Financial savings lower than anticipated for generic oral chemotherapy

image_pdfDownload PDFimage_print

A find out about by means of researchers on the College of North Carolina Eshelman College of Pharmacy and Lineberger Complete Most cancers Heart made up our minds the associated fee financial savings for a generic model of an orally administered most cancers remedy have been lower than anticipated—a discovering that questions the affect generic medicine may have on controlling well being care prices.

The researchers record within the JAMA Inner Medication that the associated fee for one fill of the generic type of the chemotherapy remedy capecitabine used to be $2,328 remaining yr. That value used to be 36 % not up to the projected branded drug value in 2016—a financial savings the researchers deemed modest in comparison to discounts observed for different generic medicine.

“For this oral most cancers remedy, we do not see the extent of value relief that we might be expecting for generic drug access,” mentioned the find out about’s senior creator Stacie Dusetzina, PhD, a UNC Lineberger member and assistant professor within the UNC Eshelman College of Pharmacy.

Dusetzina mentioned pageant from generic medicine has been a very powerful instrument for curtailing clinical prices and increasing remedy get right of entry to. On the identical time, corporations would possibly use generic value discounts as a rationale for environment upper costs for brand-name medicine, with the justification that costs can be considerably decrease after generics input the marketplace.

Capecitabine used to be one of the most first high-priced, orally administered most cancers remedies to lose patent coverage in the USA, the researchers record. They discovered that will increase in the cost of the brand-name drug, and a smaller-than-expected relief in the cost of the generic variations of the remedy, reduced the affect of generic pageant on costs 3 years after the brand-name drug got here off patent.

“The usage of capecitabine as a case find out about for the possible impact of generic pageant for orally-administered anti-cancer remedies, we discovered that discounts within the listing value have been extra modest than the ones noticed for different medicine with the similar collection of generic marketplace competition,” mentioned the find out about’s first creator Ashley Cole, MPH, a doctoral pupil and graduate analysis assistant within the UNC Eshelman College of Pharmacy.

The researchers used industrial insurance coverage claims information to estimate prescription costs for branded and generic capecitabine between 2002 and 2016. Capecitabine misplaced patent coverage in 2013, and in step with the researchers’ information, the primary fill for the generic selection used to be in March of 2014. The cost of a typical one-month provide of generic capecitabine averaged $2,598 in 2014, best 17 % under the projected branded drug value. By means of 2016, the typical generic value dropped to $2,328, which used to be 36 % under the projected branded drug value. Different research have discovered better financial savings for generic access, even in settings with a identical collection of competition.

In addition they made up our minds that brand-name drug costs larger over the years, and generic costs adopted go well with. In 2016, the cost of the generic capecitabine used to be very similar to the listing value of the brand-name drug in 2010, and it used to be 70 % upper than the brand-name drug’s listing value in 2002.

“The cost of capecitabine has greater than doubled since 2002, so even after generic access, the fee paid by means of well being plans continues to be upper than the branded drug’s authentic listing value after you alter for inflation,” Dusetzina mentioned. “If costs after generic access are in the end upper than authentic listing costs, then it’s not transparent that sufferers could have more uncomplicated get right of entry to to remedy following generic access.”

On this find out about of commercially insured sufferers, maximum sufferers had decrease out-of-pocket prices after generic access. On the other hand, about 10 % of folks paid greater than $100 for one fill of the drugs.

“As we see extra sufferers enrolled in excessive deductible well being plans, paying deductibles or co-insurance for his or her medicine, this loss of value relief would possibly without delay affect sufferers,” Dusetzina mentioned.

The findings will have coverage implications. Encouraging tough generic pageant may assist keep an eye on well being care prices, Dusetzina mentioned, because the collection of producers providing generic merchandise has been discovered to be similar to worth discounts.

“There may be an ongoing nationwide dialog round prescription drug costs, specifically forte medicine, like the ones utilized in oncology,” Cole mentioned. “Some have prompt that generic price cutting war can be a market-based option to this drawback. Our find out about supplies early proof that generic pageant by myself is probably not sufficient to rein within the excessive costs for orally administered most cancers remedies.”


Discover additional:
FDA takes steps to spice up generic pageant, prohibit costs

Magazine reference:
JAMA Inner Medication

Equipped by means of:
UNC Lineberger Complete Most cancers Heart

Tagged with:

About author

Related Articles